Assessing functional and structural cardiotoxicity in cultured human iPSC-cardiomyocytes in a single plate format by Guo, Liang et al.
HAL Id: hal-01669498
https://hal.archives-ouvertes.fr/hal-01669498
Submitted on 20 Dec 2017
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Assessing functional and structural cardiotoxicity in
cultured human iPSC-cardiomyocytes in a single plate
format
Liang Guo, Mike Furniss, Levy Batista, Thierry Bastogne, Yan Zhuge, Joseph
Wu, Sandy Eldridge, Myrtle Davis
To cite this version:
Liang Guo, Mike Furniss, Levy Batista, Thierry Bastogne, Yan Zhuge, et al.. Assessing functional
and structural cardiotoxicity in cultured human iPSC-cardiomyocytes in a single plate format. Safety
Pharmacology Society 2017 Annual Meeting, SPS 2017, Sep 2017, Berlin, Germany. ￿hal-01669498￿
Assessing functional and structural cardiotoxicity in cultured 
human iPSC-cardiomyocytes in a single plate format  
L. Guo, M. Furniss, J. Hamre, L. Batista*, T. Bastogne*, Y. Zhuge#, J.C. Wu#, S. Eldridge†, M. Davis† 
Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research/Leidos Biomedical Research, Inc., 
 Frederick, MD 21702;   *University of Lorraine, INRIA, Vandœuvre-lès-Nancy, France  
#Stanford Cardiovascular Institute, Stanford University, Stanford, CA 94305  
†DCTD, National Cancer Institute, Bethesda, MD 20892 
   Abstract  
A comprehensive profiling of cardiotoxicity early in drug discovery and 
development can aid in reducing late-stage attrition and establishing risk-
mitigation strategies during clinical development. In most cases, multiple assay 
platforms and instrument-specified plate formats are required for this type of 
approach. In this study, we evaluated both functional and structural endpoints 
associated with cardiotoxicity in human induced pluripotent stem cell-derived 
cardiomyocytes (hiPSC-CMs) cultured in a single 384-well plate. We measured 
intracellular Ca2+ transit, caspase 3/7 activation and plasma membrane 
permeabilization sequentially in the same plate via a series of assay readouts.  A 
set of cardiac ion channel modulators (dofetilide, sotalol, nifedipine and 
mexiletine) and chemotherapeutics (tamoxifen, nilotinib, sunitinib and 
doxorubicin) was tested at clinically relevant concentrations for effects on 
intracellular Ca 2+ transits after a short-term (30 minutes) exposure, and plasma 
membrane permeabilization and caspase 3/7 activation after a long-term (72 
hours) exposure. Intracellular Ca2+ transits were monitored by fluorescent 
images taken with a high-speed camera in beating cardiomyocytes loaded with 
Cal520® Ca2+ dye, permeabilized plasma membrane (for dead-cell detection) 
was identified with live-stain DRAQ7TM nuclear dye and activation of caspase 3/7 
was determined biochemically with the Caspase-Glo® 3/7 Assay kit. Multiple 
endpoints derived from Ca 2+ transits, including beat rate, calcium transit duration 
(CTD) measured at 30% or 90% from peak and corrected by inter-peak interval 
(IPI), along with CTD triangulation, beat rhythm, short- or long-term variability of 
CTD90 and IPI Poincaré plots, were used to assess drug effects on intracellular 
Ca2+ cycling and arrhythmogenicity. Increases in positive nuclear staining for 
DRAQ7TM  and caspase 3/7 activity represented structural cardiotoxicity. We 
found that increased CTD triangulation, development of arrhythmic events and 
both the short- and long-term variability of CTD90 or IPI were robust indicators of 
functional effects. Positive nuclear staining for DRAQ7TM was a robust indicator 
of structural effects. Accordingly, dofetilide and sotalol were identified as primarily 
arrhythmogenic, doxorubicin was primarily structurally toxic, while nilotinib and 
sunitinib were both arrhythmogenic and structurally toxic. The use of these 
endpoints in a single plate format simplifies the cardiotoxicity assessment and 
does not require multiple cell plates for measurements.  
Introduction 
Cardiotoxicity is frequently a dose-limiting toxicity associated with many 
highly efficacious chemotherapeutics that include both classic cytotoxic 
or cytostatic agents, such as doxorubicin or other anthracycline analogs, 
and newly developed targeted anti-cancer molecules such as protein 
kinase inhibitors (i.e. sunitinib, dasatinib and nilotinib). As this adverse 
effect can be manifested by either structural damage (i.e. 
cardiomyopathy and heart failure) or functional alteration (i.e. arrhythmia 
and sudden cardiac death),  evaluation on risks to induce both structural 
and functional cardiotoxicity should be included in preclinical safety  
profiling of each new anti-cancer drug prior to the first dose in human. 
  
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) represent  a novel cellular model system to test for cardiotoxicity 
and are being used  increasingly  with a wide variety of analytic platforms 
in study of cardiac biology and drug safety testing. In this study, we 
developed an image-based, multiplex assay  that enables interrogation 
of  both functional and structural toxicity endpoints in a single plate 
format.  
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Ca2+ transits of beating cardiomyocytes: 









































Methods & Materials 
Cells: 
Cryopreserved iPSC-cardiomyocytes were provided by  Dr. Joseph C. 
Wu and Stanford Cardiovascular Institute (SCVI) Biobank 
 
Reagents: 
RPMI 1640, BD Matrigel (Fisher/Corning); B27-insulin, DMEM/F12 
(Gibco/Life Science); Accutase (Sigma); Cal-520® Ca2+ dye (AAT 
Bioquest), DRAQ7TM  DNA dye (abcam), Caspase-Glo 3/7assay kit 
(Promega); Dofetilide, sotalol, nifedipine, mexiletine, tamoxifen, nilotinib, 
sunitinib and doxorubicin (NCI Compound Repository)  
 
Biomarkers: 
Ca2+ transits: contractile function, repolarization-delay, arrhythmia 
DNA stain: permeabilization of plasma membrane (cell death) 













Cells plated                                      Replated               Assays for Ca2+ transit     DNA stain + Caspase 3/7 
Tecan plate reader 
IN-Cell Analyzer (HCA) 6-well plate 
1 week 30 min and 72 hrs 





384-well optic plate 







Parameters: Beat rate, Inter-Peak Interval (IPI), [Ca2+] baseline, amplitude, rising rate 
(RR), falling rate (FR), transit duration 30 or 90 (CTD30 or CTD90), corrected CTD30 or 
90 by IPI (CTDc = CTD(n)/IPI(n-1); Triangulation index: = CTD90/CTD30 
Permeabilization of plasma membrane 
Figure 5. Representative images of nuclear stains 
Pre-dose 
Fibrillation                                               Beat arrest																			
Early after-depolarization 
(EAD) 
CTD prolongation + EADs                         Tachycardia 
Activation of apoptosis 
Figure 6. Caspase 3/7 activity 
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Table 1. Summary of effects on Ca2+ transit parameters 
Discussion & Conclusion 
q  Ca2+ transits were sensitive to ion channel modulators, with changes 
in beat rate and Ca2+ transit amplitude; EADs, beat-to-beat variability 
and triangulation of CTD were more specific than CTD lengthening to 
predict arrhythmogenesis 
q  Caspase 3/7 activity was a sensitive indicator of insults to hiPSC-CMs 
but increased nuclear stains of impermeable DNA dye was more 
robust to label structural cardiotoxicity 
(mean ± SEM,   
n = 3-6 wells/group;  
#, P < 0.05 compared  to 
vehicle with t-test;  
ND, not determined) 
Data analysis: 
Measurement of beat-to-beat Ca2+ transits was  performed 
by CYBERnano i-Cardio platform; treatment-related 
changes in each endpoint were shown as % of  the baseline 
value. Cells stained positive with DRAQ7 were shown as % 
of total nuclear (DAPI) counts and Caspase 3/7 activity was 
quantified as the luminescence intensity in each well. 
Statistic analysis was conducted with Student’s t-test. 
§  SD1: standard deviation of short-term variability  
§  SD2: standard deviation of long-term variability 
§  A cut-off > 1.6 to mark arrhythmogenic drugs  




Vehicle 0.1%	DMSO 106 ± 1 106 ± 2 104 ± 5 107 ± 5 113 ± 4 93 ± 2 94 ± 2 96 ± 1 95 ± 1 102 ± 1
0.003 132# ± 9 98 ± 1 68# ± 4 82# ± 5 84# ± 9 88 ± 5 93 ± 11 115# ± 1 121# ± 8 95 ± 6
0.01 155# ± 7 104 ± 4 56# ± 6 61# ± 19 63# ± 21 82# ± 1 71# ± 11 126# ± 5 108 ± 16 121# ± 12
0.03 213# ± 3 96 ± 1 27# ± 0 22# ± 0 39# ± 2 54# ± 0 37# ± 1 114# ± 2 79# ± 1 145# ± 4
0.1 ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND
0.1 104 ± 1 116 ± 1 94 ± 2 94 ± 3 101 ± 2 92 ± 2 89 ± 1 96 ± 1 93 ± 2 103 ± 3
1 104 ± 2 112 ± 4 90 ± 6 90 ± 2 92 ± 5 95 ± 1 91 ± 1 99 ± 0 95 ± 1 104 ± 0
10 100 ± 2 109 ± 2 93 ± 4 106 ± 9 94 ± 5 105# ± 2 112# ± 6 105 ± 2 111# ± 4 95 ± 3
100 111 ± 1 74# ± 2 19# ± 0 15# ± 2 20# ± 1 53# ± 3 42# ± 3 127# ± 6 99 ± 6 141# ± 4
0.001 99 ± 4 113 ± 3 98 ± 1 103 ± 9 101 ± 3 92 ± 2 88 ± 0 96 ± 3 92 ± 3 105 ± 2
0.01 107 ± 3 111 ± 4 112 ± 2 115 ± 5 118 ± 4 93 ± 1 90 ± 1 100 ± 2 97 ± 3 103 ± 1
0.1 76# ± 3 70# ± 1 54# ± 3 52# ± 8 57# ± 3 51# ± 1 42# ± 0 49# ± 2 48# ± 2 101 ± 1
1 ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND
0.1 103 ± 2 117 ± 3 95 ± 2 91 ± 4 91 ± 2 97 ± 3 91 ± 4 99 ± 4 93 ± 5 107 ± 2
1 97 ± 1 118 ± 2 103 ± 2 104 ± 2 99 ± 1 98 ± 1 94 ± 2 94 ± 1 90 ± 1 104 ± 1
10 96 ± 2 106 ± 2 89# ± 5 84# ± 3 87# ± 3 100 ± 1 97 ± 2 96 ± 3 94 ± 2 102 ± 2
100 90# ± 3 107 ± 5 49# ± 1 55# ± 3 40# ± 4 104 ± 5 91 ± 1 89 ± 2 78# ± 3 110 ± 7
0.1 114 ± 1 95 ± 2 89 ± 3 82 ± 7 105 ± 5 85 ± 2 83 ± 4 97 ± 2 95 ± 2 103 ± 1
0.3 110 ± 2 107 ± 5 112 ± 10 117 ± 11 126 ± 13 88 ± 2 88 ± 3 97 ± 2 96 ± 4 101 ± 2
1 110 ± 2 94 ± 1 96 ± 4 93 ± 6 95 ± 7 86 ± 2 86 ± 3 95 ± 3 95 ± 5 101 ± 2
3 100 ± 0 97 ± 3 96 ± 12 96 ± 11 97 ± 15 95 ± 4 88 ± 10 94 ± 5 88 ± 10 108 ± 7
1 98 ± 1 99 ± 2 83# ± 1 85# ± 5 86# ± 11 107 ± 6 114# ± 6 104 ± 6 111# ± 7 94 ± 2
3 83# ± 13 98 ± 3 71# ± 7 80# ± 9 49# ± 17 149# ± 35 118# ± 5 114# ± 4 97 ± 13 124# ± 10
10 162# ± 7 92# ± 0 27# ± 3 14# ± 2 21# ± 2 73# ± 2 33# ± 2 115# ± 2 52# ± 2 234# ± 14
30 ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND ND ± ND
0.1 111 ± 2 110 ± 0 96 ± 6 108 ± 3 117 ± 9 85 ± 1 86 ± 2 95 ± 1 96 ± 1 99 ± 1
0.3 104 ± 5 108 ± 2 87# ± 3 117 ± 11 100 ± 5 95 ± 2 105 ± 6 99 ± 6 110 ± 12 91 ± 4
1 88# ± 3 110 ± 3 75# ± 4 87# ± 7 72# ± 4 107# ± 3 111# ± 3 94 ± 3 98 ± 4 96 ± 2
3 75# ± 3 123# ± 3 49# ± 3 48# ± 6 34# ± 3 117# ± 6 96 ± 4 87 ± 5 71# ± 1 124# ± 9
0 116 ± 2 109 ± 2 91 ± 2 96 ± 4 102 ± 3 87 ± 2 84 ± 3 100 ± 2 96 ± 2 104 ± 1
0.3 117 ± 5 112 ± 2 100 ± 8 110 ± 7 110 ± 9 87 ± 1 84 ± 1 102 ± 4 98 ± 5 104 ± 2
1 115 ± 2 106 ± 3 96 ± 3 101 ± 7 104 ± 4 89 ± 2 86 ± 3 102 ± 3 99 ± 5 104 ± 2




















CTD prolongation/decreased beat rate 
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